InSightec's ExAblate system shows long-lasting benefits
This article was originally published in Clinica
Executive Summary
Israel-based InSightec says that long-term trial data are now available to support the use of its minimally-invasive ExAblate 2000 system for treating uterine fibroids. The technology, which combines ultrasound and MR, could provide a viable alternative to hysterectomy, claim study researchers from Harvard Medical School in Boston, Massachusetts.